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Introduction
Infl ammation initiated by an immune response targets 
epithelial cells, leading to cytotoxic eff ects, and is a key 
driver of several disease conditions in the gastrointestinal 
(GI) tract [1]. Chronic infl ammation leads to increased 
oxidative stress and long-term consequences, most 
notably cancer [2]. Oxidative stress is caused, in part, by 
highly reactive oxygen species (ROS) and nitrogen species 
(for example, superoxide anions, hydrogen peroxide, 
nitric oxide, and peroxynitrite), which can damage pro-
teins, lipids, DNA, and organelles, leading to altered 
pheno typic patterns, the induction of metaplasia, the 
transformation of the epithelium, and the emergence of 
cancer [2,3].
Infl ammation-associated conditions in the GI tract 
include gastroesophageal refl ux disease (GERD), Barrett’s 
esophagus (BE), graft-versus-host disease (GVHD), and 
infl ammatory bowel disease (IBD; that is, ulcerative 
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colitis and Crohn’s disease). Induction of GERD and BE 
requires gastric acid and bile refl ux to induce tissue 
injury, which results in the release of proinfl ammatory 
cytokines and subsequent recruitment of infl ammatory 
cells [4-6], while GVHD results from donor-derived 
T lymphocytes damaging host tissue in response to MHC 
disparities [7], and ulcerative colitis and Crohn’s disease 
are caused, in part, by dysregulation of mucosal immunity 
[8]. Th ese diseases are important US healthcare concerns 
associated with signifi cant morbidity and mortality 
[9-12].
Knowledge gaps
Mouse transgenic and surgical models have been the 
primary means of mechanistic studies for investigating 
infl ammation-based GI diseases. While these models 
have been useful, they have obvious limitations because 
mice do not normally develop BE or ulcerative colitis 
[13]. Improved models based on human cells and tissues 
are urgently needed to understand pathogenesis as well 
as to explore novel therapeutic strategies. Th e lack of 
robust models has been a major impediment to these 
fi elds.
Cell culture has been used in several forms for the 
study of GI disease [14]. Th e use of human cells in tissue 
culture systems, such as proposed here, allows for the 
ability to mimic the in vivo interplay between the epi-
thelium, immune cells, and the underlying stroma, 
providing a microphysiologically relevant environment 
[14] (Figure  1a). Immune cells activated in response to 
tissue injury or other mechanisms are signifi cant 
producers of ROS, including hydrogen peroxide, and 
secrete cytokines that further amplify endogenous and 
exogenous ROS (Figure 1b,c). In the esophagus and intes-
tine, esophagitis and acute IBD elicit the expression of T-
helper type 1 proinfl ammatory cytokines such as IL-1β, 
IL-8, and IFNγ, while BE and the later stages of IBD 
present with a predominantly T-helper type  2 humoral 
response, with signifi cantly increased levels of IL-4 
[15,16]. However, the mechanism by which this infl am-
matory process results in metaplasia, dysplasia, and 
cancer is not known.
Current models suggest ROS generated by immune cell 
responses induce DNA single and double-stranded breaks 
or modify DNA bases by forming adducts (Figure  1a). 
Th e major forms of oxidative DNA damage are nonbulky 
lesions such as 8-oxo-2’-deoxyguanosine and thymine 
glycol [17]. Th ese modifi cations can lead to base mis-
pairing and point mutations that, if not corrected prior to 
DNA replication, can cause mutations that activate 
oncogenes or inactivate tumor suppressors [18]. 
Furthermore, epigenetic changes in gene expression can 
also enhance disease progression [19]. Using artifi cial 
approaches (addition of hydrogen peroxide to cell 
cultures), oxidative stress was recently established to 
profoundly alter epigenetic patterning in vitro [17]. Using 
physiologically rele vant conditions, however, it remains 
unproven whether the oxidative stress associated with 
infl ammatory responses is the primary driver of the 
pathogenesis of BE, GVHD, and IBD, and the dysplasia 
and cancer associated with BE and IBD.
Esophageal three-dimensional (3D) organotypic culture 
(OTC) methods utilize epithelial cells grown on top of 
collagen/Matrigel matrices containing human fetal eso-
phageal fi broblasts [20]. OTC methods provide a highly 
physiological relevant model for studying esopha geal 
squamous epithelial growth and diff erentiation. However, 
the full potential of this culture system to model human 
disease conditions such as BE has not been fully explored. 
Fibroblasts are an essential compo nent of the 3D OTC 
system; they remodel the matrix and secrete factors that 
support squamous epithelial cell proliferation and 
diff erentiation [20]. BE epithelial cells probably require 
diff erent factors to sustain their growth. Several studies 
have identifi ed some of these factors; in vivo they include 
bone morphogenetic protein  4 and wingless int-1 
protein-2 [21,22], and in vitro they include Noggin, wing-
less int-1 protein-3a, and R-spondin-1 [23]. In addition, 
the activity of the oncogene cyclooxygenase-2 is induced 
in fi broblasts as well as in the epithelium in GERD and 
BE [24]. Our laboratory previously demon strated that 
endogenous overexpression of cyclooxy genase-2 in 
epithelial cells in 3D OTC results in the development of 
intestinal mucin-fi lled epithelial cysts, consistent with 
the progression of BE development [25]. Nevertheless, 
the extent that factors produced from fi broblasts 
infl uence BE disease development and/or progression is 
largely unknown.
In 2011, four groups independently published descrip-
tions of methods by which human intestinal and colonic 
stem cells can be maintained and expanded in culture to 
mimic in vivo microenvironments [23,26-28] (Figure 2a). 
Th ese techniques built upon and extended a slightly 
older, more established method of culturing mouse small 
intestine stem cells [29]. In this culture method, human 
intestinal and colonic crypts or purifi ed stem cells are 
embedded in Matrigel. Over several days these cells form 
spherical or elongated oval structures with a crypt-like 
lumen, referred to as human enterospheres [30] 
(Figure 2b). Small intestine and colon spheres can expand 
into multilobulated enteroids (Figure  2c) and colonoids 
that mimic the ordered structure of the epithelium 
complete with crypts containing multipotent columnar 
base stem cells and Paneth cells. Th e remaining cell types, 
including enterocytes, goblet cells, and enteroendocrine 
cells [23,30], can be observed in larger cysts away from 
the stem cell compartment (Figure  2a). While the 
majority of studies conducted with human enteroids and 
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colonoids thus far have focused on stem cell charac ter-
ization and regenerative medicine, there is immense 
potential for this culture system in GI research, 
particularly to model GVHD and IBD. However, they 
have not as yet been widely adopted to model these and 
other human disease conditions.
Future needs and research directions
Our work seeks to develop novel multicellular in vitro 
human tissue engineered models that physiologically 
recapitulate the acute and chronic infl ammatory micro-
environment in order to model the eff ects of oxidative 
injury on the epithelial cells of the esophagus and intestine. 
Th ese studies are anticipated to yield well-charac terized 
culture systems that are representative of the pathogenesis 
of GERD, BE, GVHD, and IBD, thereby providing useful 
laboratory models for these conditions. Experimental 
models for these conditions utilizing human tissues and 
cells are an unmet research imperative.
In addition, we anticipate more specifi c products of our 
eff orts. Th e development of a dynamic multicellular 
system to physiologically model infl ammation will permit 
a more mechanistic understanding of the contributions 
of infi ltrating immune cells and oxidative stress to DNA 
damage and epigenetic changes, particularly regarding 
their contribution to the progression to dysplasia and 
cancer. Moreover, these novel human cell tissue models 
can place human mucosal immunology research back in 
its appropriate context; that is, human epithelial systems. 
Pursuit of this end will require modifi cations of our 
currently established 3D organotypic and intestinal 
enteroid/colonoid culture systems to refl ect the 
infl ammatory processes active during human diseases 
such as GERD, BE, GVHD, and IBD. Lastly, these human 
cell-based models of chronic infl ammatory conditions 
can serve as a platform for testing novel therapeutic 
drugs and chemopreventive agents.
We are presently pursuing several important research 
directions. Th e fi rst is to better characterize the contri-
butions of fi broblasts to the growth and diff erentiation of 
the squamous epithelium in the OTC system. Specifi cally, 
we are exploring whether fi broblasts function primarily 
to remodel the underlying matrix by altering physical 
properties such as stiff ness, or instead secrete required 
growth and maintenance factors, or some combination of 
both. Moreover, we are investigating whether we can 
engineer the fi broblasts to secrete other growth factors 
that support columnar epithelial growth, to determine 
whether this can promote epithelial metaplasia as 
observed in BE.
Figure 1. Modeling infl ammation in the esophagus. (a) Diagram illustrating how activated immune cells produce signifi cant amounts of 
reactive oxygen species (ROS), resulting in increased oxidative stress and DNA damage, which in turn disrupts the integrity of the epithelium, 
leading to apoptosis, and contributing to the evolution of diseases including Barrett’s esophagus (BE) and cancer. (b), (c) Histological analysis of 
esophageal keratinocytes grown under organotypic conditions in the presence of active immune cells.
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We are actively exploring modifi cations to both the 
esophageal OTC and intestinal enteroid/organoid culture 
systems that will permit the inclusion of viable purifi ed 
human immune cells (Figures  1b,c and 2b). We plan to 
further refi ne the human OTC and intestinal enteroid/
colonoid cultures to include additional microenviron-
mental cell types and factors to better and more 
physiologically model human disease. For instance, 
eliciting a polarized response of purifi ed human immune 
cells against the mismatched human leukocyte antigen of 
the growing human enteroid would provide an excellent 
model for GVHD. Once optimized, these co-culture 
systems could evaluate the effi  cacies of novel immuno-
suppressant drugs and strategies to treat GVHD.
Conclusion
Our research eff orts are focused on developing physio-
logically relevant human cell-based tissue culture models 
for chronic infl ammatory conditions of the GI tract. With 
these systems we will mechanistically explore the eff ect 
of the infl ammatory response on epithelial oxidative 
stress and DNA damage. Ultimately, these novel model 
systems have the potential to permit the rapid testing of 
hypotheses and advance our understanding of chronic 
Figure 2. Modeling infl ammation in the intestine. (a) Diagram depicting the structure of an intestinal crypt in vivo, as well as the resulting in vitro 
organoid. The impact of oxidative stress and DNA damage resulting from reactive oxygen species (ROS)-producing immune cells is also shown. 
CBC, columnar base stem cells. (b) Human organoid co-cultured with dsRed-labeled mouse splenocytes (400×). (c) Human intestinal organoid 
9 days post isolation (100×).
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infl ammatory disorders. Moreover, this research will 
foster the development of novel therapeutic and 
preventive strategies that will improve the lives and well-
being of patients affl  icted with these important clinical 
conditions.
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